Clinical Assessment Of GW815SF Salmeterol/Fluticasone Propionate(HFA MDI) In Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-

• Status: Completed
• Trial end date: 2007-11-01

Summary

This study evaluates the long-term (24-week) safety and efficacy of GW815SF Salmeterol/fluticasone propionate(HFA MDI) 50/100mcg(administered as 2 inhalations of 25/50mcg) bid in pediatric patients with bronchial asthma.

• Phase: Phase 3

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Fluticasone; Salmeterol Xinafoate; Xhance